China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary Double Crane Limin obtained the approval for the quality and efficacy consistency evaluation of its famotidine injection from China's medical products administrator.
Famotidine is suitable for upper gastrointestinal bleeding caused by ulcers, according to a Jan. 4 filing with the Shanghai bourse.
Shares of the pharmaceutical company closed 3% higher Monday.